![Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection | Business Wire Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection | Business Wire](https://mms.businesswire.com/media/20200316005177/en/739014/23/teva_RGB_JPEG.jpg)
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection | Business Wire
![Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) Due to Particulate Matter | Business Wire Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) Due to Particulate Matter | Business Wire](https://mms.businesswire.com/media/20150724005534/en/478384/5/Adrucil2.jpg)
Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) Due to Particulate Matter | Business Wire
![Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) Due to Particulate Matter | Business Wire Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) Due to Particulate Matter | Business Wire](https://mms.businesswire.com/media/20150724005534/en/478383/5/2302506_306-30-10408_crop.jpg)